ClouDr Group Valuation
Is H3L undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of H3L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate H3L's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate H3L's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for H3L?
Key metric: As H3L is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is H3L's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | CN¥4.01b |
| Market Cap | CN¥671.00m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | -3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does H3L's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.3x | ||
HAEK HAEMATO | 0.2x | n/a | €66.9m |
ILM1 Medios | 0.2x | 6.1% | €328.6m |
TLIK Arzneiwerk VIDA | 0.07x | n/a | €4.4m |
V3V VITA 34 | 0.9x | 2.9% | €72.2m |
H3L ClouDr Group | 0.2x | 23.5% | €722.1m |
Price-To-Sales vs Peers: H3L is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.3x).
Price to Sales Ratio vs Industry
How does H3L's PS Ratio compare vs other companies in the DE Healthcare Industry?
Price-To-Sales vs Industry: H3L is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Healthcare industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is H3L's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 0.7x |
Price-To-Sales vs Fair Ratio: H3L is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sensus Healthcare
US$143.9m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$8.25
7D
4.4%
1Y
263.8%
Shandong Weigao Group Medical Polymer
HK$20.2b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.9%
1Y
-37.7%
LNA Santé
€240.3m
Engages in the management and operation of health establishments.
2N3
€23.00
7D
1.5%
1Y
17.7%